769 results on '"Watabe, Tadashi"'
Search Results
2. Detection support of lesions in patients with prostate cancer using 18F-PSMA 1007 PET/CT
3. Abnormal localized [18F]FDG accumulation in a Hoffman 3D brain phantom caused by Pseudomonas aeruginosa and Stenotrophomonas maltophilia
4. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial
5. Vision transformer to differentiate between benign and malignant slices in 18F-FDG PET/CT
6. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics
7. Association of circulating tumor HPV16DNA levels and quantitative PET parameters in patients with HPV-positive head and neck squamous cell carcinoma
8. Expression of fibroblast activation protein in intrathoracic solitary fibrous tumor
9. Epithelioid granuloma mimicking lung cancer showed intense uptake on [18F]FAPI-74 PET
10. Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
11. Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological Comparison
12. Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer
13. Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer
14. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations
15. Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose–positron emission tomography to differentiate between benign and malignant lesions
16. Activated fibroblasts in muscle sarcoidosis revealed by [18F]FAPI-74 PET
17. Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics
18. Preclinical Evaluation of Biodistribution and Toxicity of [211At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer
19. Improved Stability and Practicality for Synthesis of 4-Borono-2-[18F]fluoro-l-phenylalanine by Combination of [18O]O2 Single-Use and [18F]CH3COOF Labeling Agents
20. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
21. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST
22. Development of artificial intelligence for automated measurement of cervical lordosis on lateral radiographs
23. Multi-modal 3D imaging of radionuclides using multiple hybrid Compton cameras
24. New regional drug delivery system by direct epicardial placement of slow-release prostacyclin agonist promise therapeutic angiogenesis in a porcine chronic myocardial infarction
25. Pimitespib is effective on cecal GIST in a mouse model of familial GISTs with KIT-Asp820Tyr mutation through KIT signaling inhibition
26. Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer
27. FDG-PET/CT for Large-Vessel Vasculitis
28. Basic Science of PET Imaging for Inflammatory Diseases
29. Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)
30. Abstract 11403: Systemic Administration of High Mobility Group Box 1 Fragment Improves Cardiac Functions via Activating Tissue Healing Pathway of Bone-Marrow Mesenchymal Stem Cell in a Porcine Ischemic Cardiomyopathy Model
31. Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
32. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
33. Preclinical Evaluation of Biodistribution and Toxicity of [ 211 At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.
34. Manual on the proper use of the 211At-labeled PSMA ligand ([211At]PSMA-5) for clinical trials of targeted alpha therapy (1st edition).
35. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial.
36. Vision transformer to differentiate between benign and malignant slices in 18F-FDG PET/CT.
37. Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice
38. Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients
39. Epithelioid granuloma mimicking lung cancer showed intense uptake on [18F]FAPI-74 PET
40. Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with89Zr or211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
41. Individual dosimetry system for targeted alpha therapy based on PHITS coupled with microdosimetric kinetic model
42. Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
43. Synthesis of [211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
44. One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
45. Usefulness of semi-automatic harmonization strategy of standardized uptake values for multicenter PET studies
46. Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer
47. Response to the letter to the editor
48. Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling
49. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma
50. Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.